AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.
Location: United States
Employees: 11-50
Total raised: $75.23M
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| - | Indaco Ven... | indacosgr.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.02.2021 | Series A | $42.42M | - |
| 28.07.2020 | Series A | $32.81M | - |
Mentions in press and media 13
| Date | Title | Description |
| 14.01.2026 | Landmark AbbVie-Trump Deal Reshapes Drug Access, Ignites U.S. Pharma Investment | A monumental three-year agreement reshapes pharmaceutical access. The Trump administration and AbbVie forged a new path. AbbVie will dramatically reduce drug prices within Medicaid. It will also expand direct-to-patient offerings through th... |
| 13.01.2026 | AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans | AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx AbbVie will commit $100 billion in U.S. research and development (R&D) and capit... |
| 13.01.2026 | AbbVie And Trump Administration Strike $100 Billion Deal Tied To Medicaid Prices, Direct-To-Patient Drug Access, And U.S. Investment Plan | AbbVie announced it has reached a voluntary, three-year agreement with the Trump administration aimed at expanding access to medicines and lowering costs for Americans, while the company commits to a decade-long investment push in U.S. rese... |
| 17.03.2024 | AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site | US$223 million expansion will add biologics capacity to AbbVie manufacturing network Singapore manufacturing site to grow to more than 500 employees following expansion Construction will commence immediately with facilities becoming operati... |
| 26.01.2024 | AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site | US$223 million expansion will add biologics capacity to AbbVie manufacturing network Singapore manufacturing site to grow to more than 500 employees following expansion Construction will commence immediately with facilities becoming operati... |
| 06.03.2022 | AbbVie Completes Acquisition of Syndesi Therapeutics, for Up To USD1 Billion | AbbVie (NYSE: ABBV) completed the acquisition of Syndesi Therapeutics SA, a Belgium-based clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cogni... |
| 08.10.2021 | Flagship turns to Novartis HR guru in latest addition; David Grainger saddles up to new position at Centessa while Pfizer's Rod MacKenzie prepares to ride into the sunset... | David Grainger → In a development that just seemed to add up neatly given Medicxi’s involvement with Centessa, the brainchild of Francesco de Rubertis has named fellow Medicxi co-founder David Grainger as chief innovation of... |
| 04.10.2021 | Sanofi : Enthera Pharmaceuticals Enthera Pharmaceuticals appoints Antonio Speziale as Chief Medical Officer; Antonio Speziale joins Enthera with drug development and commercialization experience from ... | Milan, Italy -- Enthera Pharmaceuticals (Enthera), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, has appointed Antonio Speziale as Chief Medical... |
| 01.02.2021 | Enthera Pharmaceuticals Extends Series A Totalling €35M | Enthera Pharmaceuticals, a Milan, Italy-based biotech company, closed its Series A financing, with a total financing of €35m. The Roche Venture Fund joined an international investment syndicate following the fundraising’s first close of €28... |
| 28.01.2021 | Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m | MILAN–(BUSINESS WIRE)–Jan 28, 2021– Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilit... |
Show more